Epigenetics in a spectrum of myeloid diseases and its exploitation for therapy
Mutations in genes encoding chromatin regulators are early events contributing to de-veloping asymptomatic clonal hematopoiesis of indeterminate potential and its frequent progression to myeloid diseases with increasing severity. We focus on the subset of myeloid diseases encompassing myelodysplasti...
| Autores: | , , , |
|---|---|
| Formato: | artículo |
| Fecha de publicación: | 2021 |
| País: | España |
| Recursos: | Universitat Autònoma de Barcelona |
| Repositorio: | Dipòsit Digital de Documents de la UAB |
| Idioma: | inglés |
| OAI Identifier: | oai:ddd.uab.cat:270647 |
| Acesso em linha: | https://ddd.uab.cat/record/270647 https://dx.doi.org/urn:doi:10.3390/cancers13071746 |
| Access Level: | acceso abierto |
| Palavra-chave: | Epigenetics Chromatin Epigenetic regulators Clonal hematopoiesis of indeterminate potential (CHIP) Myelodysplastic syndromes (MDS) Acute myeloid leukemia (AML) Secondary acute myeloid leukemia (sAML) |
| Resumo: | Mutations in genes encoding chromatin regulators are early events contributing to de-veloping asymptomatic clonal hematopoiesis of indeterminate potential and its frequent progression to myeloid diseases with increasing severity. We focus on the subset of myeloid diseases encompassing myelodysplastic syndromes and their transformation to secondary acute myeloid leukemia. We introduce the major concepts of chromatin regulation that provide the basis of epigenetic regulation. In greater detail, we discuss those chromatin regulators that are frequently mutated in myelodysplastic syndromes. We discuss their role in the epigenetic regulation of normal hematopoiesis and the consequence of their mutation. Finally, we provide an update on the drugs interfering with chromatin regulation approved or in development for myelodysplastic syndromes and acute myeloid leukemia. |
|---|